THTuukka Hakkarainen

Tuukka Hakkarainen

*This is an algorithmically generated author record based on publicly available information.

Tuukka Hakkarainen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrating Participatory Social Innovation Into Requirements Engineering for AI Health Care Solutions: Case Study

    by Carina Dantas, Miriam Cabrita, Maciej Bobowicz, Harm Op Den Akker, Xavier Rafael-Palou, Tuukka Hakkarainen, Ira Haavisto, Fredrik Strand, Luis Marti-Bonmati, Eugen Divjak, et al.

    Background: The successful design and implementation of artificial intelligence (AI)–driven solutions in health care requires early and continuous multidisciplinary and multiprofessional collaboration. However, diverse disciplinary educational backgrounds, varying languages, and cultural or geographic differences can lead to misunderstandings. To bridge this gap, a structured approach to AI requirements specification can facilitate a shared terminology and a deep mutual understanding among stakeholders, serving both as a guide for technological development and as a means of defining clear pathways for clinical implementation. While technical requirements are well-established in traditional technology development domains, this structured approach remains relatively underused within clinical and social science contexts. Consequently, valuable insights derived from participatory and stakeholder-driven approaches are often overlooked, limiting the relevance and trustworthiness of AI systems in health care settings. Objective: This study presents a methodology for requirements gathering, specification, mapping, and verification, specifically engineered for the complex, multistakeholder environment of clinically applied AI. The methodology was implemented within the specific case of an international multidisciplinary project evaluating an AI-based prediction tool for neoadjuvant chemotherapy treatment response for breast cancer and forming a part of the developed AI validation framework. Methods: The process for AI requirements gathering, specification, and monitoring included 3 iterative rounds of discussion, engaging nearly 150 social, clinical, technical, ethical, and regulatory experts and patients across Europe, South America, North Africa, and Eurasia. It combines established requirements engineering methods (including the MoSCoW [Must have, Should have, Could have, Will not have] framework) with social innovation techniques to ensure inclusivity and contextual relevance. Results: A key finding is the successful development of a structured framework integrating participatory social innovation with formal requirements engineering in an international AI health care setting, through a traceable multisource workflow including clinical, ethical, and regulatory aspects. It is supplemented with an extensive list of 184 actionable consensus-based requirements, categorized by stakeholder group, providing valuable insights for AI researchers in the oncology field with the potential to be transferable to other digital health domains. The requirements align with the fairness, universality, traceability, usability, robustness, and explainability in the AI (FUTURE-AI) framework, ensuring the tool is trustworthy and comprehensive from a multistakeholder perspective, and ensuring comprehensive consideration of all elements of FUTURE-AI. Conclusions: The proposed methodology represents a significant advancement for requirements engineering in digital health by extending traditional technical processes to systematically incorporate nontechnical requirements from diverse global stakeholders. This unified approach is essential for ensuring AI solutions are not only technically robust but also clinically relevant, legally compliant, and socially acceptable.


  • Open Access

    Cost-Effectiveness of a Quality of Life Predictor to Guide Psychosocial Support in Breast Cancer

    by Tuukka Hakkarainen, Ira Haavisto, Mikko Nuutinen, Yrjänä Hynninen, Paula Poikonen-Saksela, Johanna Mattson, Haridimos Kondylak, Eleni Kolokotroni, Ketti Mazzocco, Berta Sousa, et al.

    Introduction: Women with breast cancer experience psychological distress, and resilience-strengthening psychosocial support may improve their quality of life (QoL). Identifying those at risk of low QoL is challenging. This study evaluated the cost-effectiveness of a machine learning-based QoL predictor to support clinical decision-making regarding psychosocial support (sample size: 660). Methods: A decision tree cost–utility model was developed to compare four decision-making strategies in offering psychosocial support: the clinician alone, the QoL predictor alone, the clinician supported by the predictor, and no prediction with no psychosocial support. QoL after one year was used as a proxy for resilience. Costs, health outcomes, and net monetary benefits (NMBs) were estimated using a one-year time horizon. Incremental cost-effectiveness ratios (ICERs) were calculated and dominance assessed. A societal scenario analysis incorporated productivity losses. A probabilistic sensitivity analysis generated cost-effectiveness acceptability curves. Results: Clinicians supported by the QoL predictor produced the highest NMB (EUR 16,349) and the greatest quality-adjusted life year (QALY) gain (0.759), with an ICER of EUR 22,892 compared with the next least costly strategy. Clinician-only prediction and predictor-only approaches were dominated or extendedly dominated. Under the societal perspective, all strategies produced negative NMB values due to productivity losses, but the overall ranking remained unchanged. The probabilistic sensitivity analysis showed that the combined clinician and predictor strategy had a 69% probability of being cost-effective at a willingness to pay threshold of EUR 30,000. Conclusions: Combining clinician judgement with the machine learning-based QoL predictor improved the targeting of psychosocial support and was the most cost-effective strategy. Further prospective and comparative studies are needed to confirm its long-term effectiveness and cost-effectiveness in clinical practice.


  • Open Access

    Requirements Engineering for AI-Driven Healthcare Solutions: A Case Study Combining Social Innovation and Multistakeholder Engagement (Preprint)

    by Carina Dantas, Miriam Cabrita, Maciej Bobowicz, Harm Op Den Akker, Xavier Rafael-Palou, Tuukka Hakkarainen, Ira Haavisto, Fredrik Strand, Luis Marti-Bonmati, Eugen Divjak, et al.

    BACKGROUND The successful design and implementation of Artificial Intelligence (AI)-driven solutions in healthcare requires early and continuous multidisciplinary and multiprofessional collaboration. However, diverse disciplinary educational backgrounds, varying languages, and cultural or geographic differences can lead to misunderstandings. To bridge this gap, a structured approach to AI requirements specification can facilitate a shared terminology and a deep mutual understanding among stakeholders, serving both as a guide for technological development and as a means of defining clear pathways for clinical implementation. While technical requirements are well-established in traditional technology development domains, this structured approach remains relatively underutilised within clinical and social science contexts. Consequently, valuable insights derived from participatory and stakeholder-driven approaches are often overlooked, limiting the relevance and trustworthiness of AI systems in healthcare settings. OBJECTIVE This study presents a methodology for requirements gathering, specification, mapping, and verification, specifically engineered for the complex, multi-stakeholder environment of clinically-applied AI. The methodology was implemented within the specific case of an international multidisciplinary project evaluating an AI-based prediction tool for neoadjuvant chemotherapy treatment response for breast cancer and forming a part of the developed AI validation framework. METHODS The process for AI requirements gathering, specification, and monitoring included three iterative rounds of discussion, engaging nearly 150 social, clinical, technical, ethical and regulatory experts, and patients, across Europe, South America, North Africa, and Eurasia. It combines established requirements engineering methods (including the MoSCoW framework) with social innovation techniques to ensure inclusivity and contextual relevance. RESULTS A key finding is the successful development of a structured framework that systematically integrates technical feasibility with critical clinical, ethical, and regulatory constraints. It is supplemented with an extensive list of 184 actionable consensus-based requirements, categorised by stakeholder group, providing valuable insights for AI researchers in the oncology field with the potential to be transferable to other digital health domains. The requirements align with the FUTURE-AI framework, ensuring the tool is trustworthy and comprehensive from a multi-stakeholder perspective, ensuring comprehensive consideration of fairness, usability, transparency, universality, robustness, and explainability. CONCLUSIONS The proposed methodology represents a significant advancement for requirements engineering in digital health by extending traditional technical processes to systematically incorporate non-technical requirements from diverse global stakeholders. This unified approach is essential for ensuring AI solutions are not only technically robust but also clinically relevant, legally compliant, and socially acceptable. CLINICALTRIAL Not applicable

  • Open Access

    Health and economic burden of herpes zoster in adults in Finland: A retrospective nationwide database study

    by Mari Kanerva, Suvi E. Heinonen, Tuukka Hakkarainen, Outi Isomeri, Marie Nishimwe, Alen Marijam, Riikka-Leena Leskelä

    The risk of herpes zoster (HZ) and its complications, such as postherpetic neuralgia (PHN), increases with age and burdens patients, the healthcare system, and society. We aimed to estimate the incidence, healthcare resource use (HCRU), and direct and indirect costs due to HZ and HZ-related complications (i.e. PHN) per age group in the adult population in Finland. This retrospective, non-interventional population-based registry study collected data from four different registers over 2014-2019: three with nationwide coverage and one with partial nationwide coverage. International classification codes were used to identify HZ and PHN cases. The incidences of HZ and PHN were stratified annually and per age group (18-49, 50-59, 60-64, 65-69, 70-79, ≥80 years of age [YoA]). The HZ-associated HCRU, and direct and indirect costs were estimated by counting healthcare contact, medications, and their unit costs from national registries. HZ incidence rate increased with age from 1.99/1,000 persons in 18-49 YoA to 8.04/1,000 persons in ≥80 YoA over 2014-2019. PHN incidence also increased with age. The HZ 5-year recurrence rate was 4.5%. Average total annual costs of HZ amounted to €11.3 million; the individual costs of an HZ and a PHN HZ episode were €649 and €1,910, respectively. Estimated total costs were split between sick leave (37%), inpatient days (30%), outpatient visits (29%), and outpatient antiviral drugs (4%). In Finland, HZ poses a significant health and economic burden that increases with population aging, highlighting the need to consider HZ prevention.


  • Open Access

    Healthcare Resource Use and Costs of Localized Prostate Cancer Patients in Finland

    by Teemu J. Murtola, Tuukka Hakkarainen, Mari Lahelma, Paula Pennanen, Riikka-Leena Leskelä, Mika Pietilä, Petteri Hervonen, Okko-Sakari Kääriäinen, Heikki Minn, Timo K. Nykopp, et al.


  • Open Access

    Methodological approaches in the economic evaluation of prognostic and predictive companion diagnostics: a systematic scoping review

    by Tuukka Hakkarainen, Haavisto Ira, Leskelä Riikka-Leena

    This systematic scoping review aimed to identify and analyze current methodological approaches used in model-based economic evaluations (EEs) of prognostic and predictive companion diagnostics (pCDx), highlighting methodological gaps and challenges. Systematic searches were conducted in PubMed and Scopus (January 2009-March 2023). Included studies were model-based EEs, methodological papers, or reviews specifically addressing prognostic or predictive CDx. Data extraction followed modified CHEERS checklist. Results were synthesized narratively across six methodological domains. No formal risk of bias assessment was done per scoping review conventions. Eighty-eight studies were included, of which 60 were model-based EEs. Most studies utilized Markov cohort models (37%) or decision tree - Markov hybrids (30%). Quality-adjusted life-years (QALYs) were the main outcome (88%). Only 15% of studies derived clinical utility from randomized controlled trials, and fewer than half explicitly modeled diagnostic accuracy. Methodological limitations included inconsistent modeling of real-world test-treatment pathways, insufficient consideration of pretest probabilities, diagnostic thresholds, and inadequate uncertainty analyses. This review identified variability and methodological gaps in economic evaluations of pCDx. Standardizing evaluation methods, integrating real-world evidence, and systematically considering the diagnostic accuracy and uncertainty could improve robustness of pCDx evaluations. Limitations of this study included overrepresentation of breast cancer studies. OSF Registries (22 February 2023) DOI 10.17605/OSF.IO/GVFMQ.